# Akari Therapeutics Plc: overview AKTX · Nasdaq · CIK 1541157 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aktx.md) · [Financials](/companies/aktx/financials.md) · [Filings](/companies/aktx/filings.md) · [Insiders](/companies/aktx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001493152-25-022390.md) | not reported | [0.00](/filings/0001493152-26-024446.md) | [0.00](/filings/0001493152-26-037730.md) | [0.00](/filings/0001493152-25-022390.md) | not reported | [0.00](/filings/0001493152-26-024446.md) | [0.00](/filings/0001493152-26-037730.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001410578-23-000848.md) | [0.00](/filings/0000950170-24-038661.md) | [0.00](/filings/0000950170-25-054278.md) | [0.00](/filings/0001493152-26-013664.md) | [0.00](/filings/0001493152-26-013664.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aktx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $1.0m | 100,000 | | New +100,000 | | [Cresset Asset Management, LLC](/funds/1761013.md) | 2026-06-30 | $210.6k | 20,561 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $158.4k | 15,463 | | New +15,463 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $102.5k | 10,000 | Call | New +10,000 | | [IFP Advisors, Inc](/funds/1641866.md) | 2026-06-30 | $1.9k | 181 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $143 | 14 | | Added +9 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $140 | 13,745 | | New +13,745 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $82 | 8 | | New +8 | | [NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO](/funds/1141802.md) | 2026-06-30 | $72 | 7 | | New +7 | | [Truvestments Capital LLC](/funds/1750405.md) | 2026-06-30 | $10 | 1 | | Unchanged | ## Recent filings [All 739 filings](/companies/aktx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:45 ET | [8-K](/filings/0001493152-26-049446.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-049446 | | 2026-10-01 | 17:00 ET | [DEF 14A](/filings/0001493152-26-045371.md) | Proxy statement, period 2026-10-01 | 0001493152-26-045371 | | 2026-10-01 | 16:45 ET | [8-K](/filings/0001493152-26-045364.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-045364 | | 2026-08-13 | 16:02 ET | [8-K](/filings/0001493152-26-037736.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037736 | | 2026-08-13 | 16:00 ET | [10-Q](/filings/0001493152-26-037730.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037730 | | 2026-07-02 | 17:25 ET | [8-K](/filings/0001493152-26-031972.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-031972 | | 2026-06-26 | 17:15 ET | [8-K](/filings/0001493152-26-030341.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-030341 | | 2026-06-26 | 17:00 ET | [S-1/A](/filings/0001493152-26-030330.md) | Registration statement, amended | 0001493152-26-030330 | | 2026-06-04 | 16:30 ET | [DEF 14A](/filings/0001493152-26-027279.md) | Proxy statement, period 2026-06-04 | 0001493152-26-027279 | | 2026-05-22 | 16:30 ET | [8-K](/filings/0001493152-26-025037.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-025037 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013664.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1541157 - Tickers: AKTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:09 ET. No prices; not investment advice.